BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2021 10:05:39 AM | Browse: 514 | Download: 1263
 |
Received |
|
2021-01-26 07:02 |
|
Peer-Review Started |
|
2021-01-26 07:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-27 18:03 |
|
Revised |
|
2021-03-10 09:53 |
|
Second Decision |
|
2021-04-20 13:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-21 17:38 |
|
Articles in Press |
|
2021-04-21 17:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-05-07 02:04 |
|
Typeset the Manuscript |
|
2021-05-11 04:58 |
|
Publish the Manuscript Online |
|
2021-05-13 10:05 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yue Han, Wei-Hua Zhi, Fei Xu, Chen-Bo Zhang, Xiao-Qian Huang and Jian-Feng Luo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yue Han, PhD, Doctor, Doctor, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 9 Dongdan 3rd Alley, Dongcheng, Beijing 100021, China. doctorhan@163.com |
| Key Words |
Hepatocellular carcinoma; Systemic therapy; Meta-analysis; Lenvatinib; First-line; Immune therapy |
| Core Tip |
The present network meta-analysis is the first to compare data from randomized trials of all first-line systemic therapies for hepatocellular carcinoma including chemotherapy, targeted drugs, immunotherapy and combination therapies. Furthermore, the analysis represents a comprehensive cross comparison of outcomes, including tumor response rates, survival, and safety and included a sub-analysis in patients with HBV infection. Our results showed that atezolizumab plus bevacizumab was ranked first for progression-free survival and overall survival but also had the highest rate of discontinuations due to adverse events. Lenvatinib ranked first for overall response rate and second for progression-free survival. |
| Publish Date |
2021-05-13 10:05 |
| Citation |
Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i19/2415.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i19.2415 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
